Maintenance and Self-Renewal of Long-Term Reconstituting Hematopoietic Stem Cells Supported by Amniotic Fluid

Barria, Emily; Mikels, Amanda; Haas, Martín

doi:10.1089/1547328042417273

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, it could also be explained by the fact that the two potent mechanisms promoting cell differentiation, that is, cell‐cell contact and cell‐matrix contact do not influence cells floating in the amniotic fluid at very low concentration. Indeed, it has been reported that substituting serum with human amniotic fluid provides a growth milieu for adult bone marrow mouse HSC cultures in which differentiation and apoptosis are downregulated and multipotency is maintained . More data is needed to understand if the amniotic fluid is capable of maintaining stemness (e.g., culture of AFSC in pure amniotic fluid or amniotic fluid‐containing media), to determine if there is active stem cell homeostasis between the fluid and other fetal tissues and as well as the potential contribution of these cells to tissue repair/regeneration in the fetus.…”

Section: The Unknownmentioning

confidence: 99%

Concise Review: Amniotic Fluid Stem Cells: The Known, the Unknown, and Potential Regenerative Medicine Applications

2017

View full text Add to dashboard Cite

The amniotic fluid has been identified as an untapped source of cells with broad potential, which possess immunomodulatory properties and do not have the ethical and legal limitations of embryonic stem cells. CD117(c-Kit)+ cells selected from amniotic fluid have been shown to differentiate into cell lineages representing all three embryonic germ layers without generating tumors, making them ideal candidates for regenerative medicine applications. Moreover, their ability to engraft in injured organs and modulate immune and repair responses of host tissues, suggest that transplantation of such cells may be useful for the treatment of various degenerative and inflammatory diseases. Although significant questions remain regarding the origin, heterogeneous phenotype, and expansion potential of amniotic fluid stem cells, evidence to date supports their potential role as a valuable stem cell source for the field of regenerative medicine. Stem Cells 2017;35:1663-1673.

show abstract

Section: The Unknownmentioning

confidence: 99%

Concise Review: Amniotic Fluid Stem Cells: The Known, the Unknown, and Potential Regenerative Medicine Applications

2017

View full text Add to dashboard Cite

show abstract

“…An increasing number of studies have demonstrated that AFSCs have the capacity for remarkable proliferation and differentiation into multiple lineages such as chondrocytes, adipocytes, osteoblasts, myocytes, endothelial cells, neuron-like cells, and liver cells (Barria et al, 2004). An increasing number of studies have demonstrated that AFSCs have the capacity for remarkable proliferation and differentiation into multiple lineages such as chondrocytes, adipocytes, osteoblasts, myocytes, endothelial cells, neuron-like cells, and liver cells (Barria et al, 2004).…”

Section: Amniotic Fluid-derived Stem Cells (Afscs)mentioning

confidence: 99%

Stem Cells

Das

Tyagi

2014

Animal Biotechnology

View full text Add to dashboard Cite

“…Other proposed approaches are based on the treatment with pertinent growth factors, such as erythropoietin (EPO), granulocyte and granulocyte-macrophage colony stimulating factors (G-CSF and GM-CSF, respectively). [14][15][16][17][18][19] Some of these factors have already been approved as proregenerative emergency and investigative new drug to treat BM failure following aggressive radiotherapy or chemotherapy 1,18,20 Several other drugs and growth factors, as well as anti-inflammatory cytokines and chemokines and prostaglandins, have also been proposed for mitigation of ARS, based on various mechanisms, such as their anti-oxidative and anti-apoptotic activity. [21][22][23][24] Early studies employing BM or other tissue derived mesenchymal stromal/stem cells (MSC) proposed that the implanted cells take an active role in replacing the depleted cells in damaged tissues by their differentiation to various relevant mesenchymal cell types and their subsequent integration in the damaged tissues.…”

Section: Introductionmentioning

confidence: 99%

“…It also does not address damages to other organs. Other proposed approaches are based on the treatment with pertinent growth factors, such as erythropoietin (EPO), granulocyte and granulocyte‐macrophage colony stimulating factors (G‐CSF and GM‐CSF, respectively) . Some of these factors have already been approved as pro‐regenerative emergency and investigative new drug to treat BM failure following aggressive radiotherapy or chemotherapy Several other drugs and growth factors, as well as anti‐inflammatory cytokines and chemokines and prostaglandins, have also been proposed for mitigation of ARS, based on various mechanisms, such as their anti‐oxidative and anti‐apoptotic activity …”

Section: Introductionmentioning

confidence: 99%

Rescue from lethal acute radiation syndrome (ARS) with severe weight loss by secretome of intramuscularly injected human placental stromal cells

Pinzur

Akyuez

Levdansky

et al. 2018

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

BackgroundMost current cell‐based regenerative therapies are based on the indirect induction of the affected tissues repair. Xenogeneic cell‐based treatment with expanded human placenta stromal cells, predominantly from fetal origin (PLX‐RAD cells), were shown to mitigate significantly acute radiation syndrome (ARS) following high dose irradiation in mice, with expedited regain of weight loss and haematopoietic function. The current mechanistic study explores the indirect effect of the secretome of PLX‐RAD cells in the rescue of the irradiated mice.MethodsThe mitigation of the ARS was investigated following two intramuscularly (IM) injected 2 × 106 PLX‐RAD cells, 1 and 5 days following 7.7 Gy irradiation. The mice survival rate and their blood or bone marrow (BM) cell counts were followed up and correlated with multiplex immunoassay of a panel of related human proteins of PLX‐RAD derived secretome, as well as endogenous secretion of related mouse proteins. PLX‐RAD secretome was also tested in vitro for its effect on the induction of the migration of BM progenitors.ResultsA 7.7 Gy whole body mice irradiation resulted in ~25% survival by 21 days. Treatment with two IM injections of 2 × 106 PLX‐RAD cells on days 1 and 5 after irradiation mitigated highly significantly the subsequent lethal ARS, with survival rate increase to nearly 100% and fast regain of the initial weight loss (P < 0,0001). This was associated with a significant faster haematopoiesis recovery from day 9 onwards (P < 0.01). Nine out of the 65 human proteins tested were highly significantly elevated in the mouse circulation, peaking on days 6–9 after irradiation, relative to negligible levels in non‐irradiated PLX‐RAD injected mice (P < 0.01). The highly elevated proteins included human G‐CSF, GRO, MCP‐1, IL‐6 and lL‐8, reaching >500 pg/mL, while MCP‐3, ENA, Eotaxin and fractalkine levels ranged between ~60–160pg/mL. The detected radiation‐induced PLX‐RAD secretome correlated well with the timing of the fast haematopoiesis regeneration. The radiation‐induced PLX‐RAD secretome seemed to reinforce the delayed high levels secretion of related mouse endogenous cytokines, including GCSF, KC, MCP‐1 and IL‐6. Additional supportive in vitro studies also confirmed the ability of cultured PLX‐RAD secretome to induce accelerated migration of BM progenitors.ConclusionsA well‐regulated and orchestrated secretion of major pro‐regenerative BM supporting secretome in high dose irradiated mice, treated with xenogeneic IM injected PLX‐RAD cells, can explain the observed mitigation of ARS. This seemed to coincide with faster haematopoiesis regeneration, regain of severe weight loss and the increased survival rate. The ARS‐related stress signals activating the IM injected PLX‐RAD cells for the remote secretion of the relevant human proteins deserve further investigation.

show abstract

Maintenance and Self-Renewal of Long-Term Reconstituting Hematopoietic Stem Cells Supported by Amniotic Fluid

Cited by 3 publications

References 0 publications

Concise Review: Amniotic Fluid Stem Cells: The Known, the Unknown, and Potential Regenerative Medicine Applications

Concise Review: Amniotic Fluid Stem Cells: The Known, the Unknown, and Potential Regenerative Medicine Applications

Stem Cells

Rescue from lethal acute radiation syndrome (ARS) with severe weight loss by secretome of intramuscularly injected human placental stromal cells

Contact Info

Product

Resources

About